Michael V. Seiden, MD, PhD


Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks

February 04, 2016

The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.